Syrspend SF | 2017 Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend® SF PH4 oral suspensions Ferreira AO, Polonini HC, Loures da Silva S, Cerqueira de Melo VA, de Andrade L, Brandao MAF International Journal of Pharmaceutical Compounding, 21(3), 255-263 The objective of this study was to evaluate the stability of 10 commonly used APIs compounded in oral suspensions using SyrSpend SF PH4. The beyond-use date of the final products (APIs + vehicle) was at least 90 days for all suspensions with regard to both temperatures. Read more SEE PRODUCT
Syrspend SF | 2017 Limited influence of excipients in extemporaneous compounded suspensions Dijkers E, Nanhekhan V, Thorissen A, Marro D, Uriel M Hospital Pharmacy, 52(6), 428-432 The objective of this study was to assess oral suspensions with SyrSpend® SF based on tablets or capsules as a suitable alternative for using raw APIs. Based on this study, a wide range of excipients do not seem to impact the beyond-use date of different APIs compounded in SyrSpend® SF. Read more SEE PRODUCT
Pentravan | 2017 Detection of Enrofloxacin after single-dose percutaneous administration in Python regius, Boa constrictor imperator, and Acrantophis dumerili Ducrotte-Tassel A, Kirilov P, Salvi JP, Czyz I, Dore V, Marignac G, Pignon CP, Boulieu R, Perrot S Journal of Exotic Pet Medicine, 26(4), 263-269 In this study, the blood concentrations of enrofloxacin administered transdermally to 3 different reptilian species at 50 mg/kg were determined. Although the values were unquantifiable, this study confirms the absorption of enrofloxacin. Read more SEE PRODUCT
TrichoConcept | 2017 In Vitro effects of the Phytocomplex TrichoTech™ on human fibroblasts: Proliferative potential and effects on gene expression of FGF-7 and FGF-10 Amaral F, Jardim M, de Souza Antunes VM, Gomes Michelin LF, Rodrigues dos Santos BA, Vaz Barbosa CM, Gonsales Spindola D, Bincoletto C, Rocha Oliveira C Journal of Cosmetics, Dermatological Sciences and Applications, 7(1), 1-13 This study aimed to investigate the proliferative potential of Trichotech (1% and 2%) on cultured human fibroblasts and its ability to modulate the gene expression of FGF-7 and FGF-10. Trichotech was found to increase the collagen content and the expression of FGF-7 and FGF-10 in treated fibroblasts. Read more SEE PRODUCT
Pentravan | 2017 Transdermal Oxandrolone: Ex Vivo percutaneous absorption study Polonini HC, Ferreira AO, Raposo NRB, Brandao MAF Current Drug Delivery, 14(5), 696-700 The objective of this study was to evaluate the permeability of oxandrolone in human skin. 25.9% of the applied dose was able to permeate through a non-damaged skin, suggesting transdermal oxandrolone could be a viable alternative for traditional oral form. Read more SEE PRODUCT
Syrspend SF | 2016 Feasibility of Amlodipine Besylate, Chloroquine Phosphate, Dapsone, Phenytoin, Pyridoxine Hydrochloride, Sulfadiazine, Sulfasalazine, Tetracycline Hydrochloride, Trimethoprim and Zonisamide in SyrSpend® SF PH4 oral suspensions Ferreira AO, Polonini HC, Silva SL, Patricio FB, Brandao MAF, Raposo NRB Journal of Pharmaceutical and Biomedical Analysis, 118, 105-112 The objective of this study was to evaluate the feasibility of 10 commonly used active pharmaceutical ingredients (APIs) compounded in SyrSpend® SF PH4 liquid. The expiration date of the final products (API + vehicle) was at least 90 days for all suspensions with regard to both the controlled temperatures. Read more SEE PRODUCT
Syrspend SF | 2016 Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend® SF PH4 Oral Suspensions. Polonini HC, Loures S, de Araju EP, Brandao MAF, Ferreira AO International Journal of Pharmaceutical Compounding, 23(6), 352-358 The objective of this study was to evaluate the stability of 10 commonly used active pharmaceutical ingredients. The beyond-use dates of the preparations were found to be at least 90 days for all suspensions, both for controlled refrigerated temperature and room temperature. Read more SEE PRODUCT
Syrspend SF | 2016 Compatibility of Caffeine, Carvedilol, Clomipraminehydrochloride, Folic Acid, Hydrochlorothiazide, Loperamide Hydrochloride, Methotrexate, Nadolol, Naltrexone Hydrochloride and Pentoxifylline in SyrSpend® SF PH4 oral suspensions Polonini HC, Silva SL, de Almeida TR, Brandao MAF, Ferreira AO European Journal of Hospital Pharmacy: Science and Practice, 23(6), 352-358 The objective of this study was to evaluate the compatibility of 10 commonly used APIs compounded in SyrSpend SF PH4. Given the percentage of recovery of the APIs the expiration date of all products (API+vehicle) was found to be at least 90 days, for both controlled refrigerated and RT. Read more SEE PRODUCT
Syrspend SF | 2016 Stability study of 5 mg/ml Oxybutynin oral suspension in Syrspend® Lesourd F, Bellay R, Quilliec C, Lester MA, Boivin PN, Gicquel T European Journal of Hospital Pharmacy: Science and Practice, 23 issue Suppl 1(2), A210.1-A210 The aim of this study was to evaluate the physicochemical stability of 5 mg/mL oxybutynin oral suspension in Syrspend. These results indicate that microbiological stability and physical stability are acceptable but the concentration does not allow to go beyond 8 days. Read more SEE PRODUCT
Syrspend SF | 2016 Compatibility of proton pump inhibitors in a preservative-free suspending vehicle Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandao MAF, Ferreira AO European Journal of Hospital Pharmacy: Science and practice, 25(3), 150-156 The objective was to evaluate the microbiological and physicochemical compatibility of commonly used proton pump inhibitors (PPIs) esomeprazole, lansoprazole, omeprazole and pantoprazole compounded using SyrSpend® SF Alka. Beyond-use dates of maximum 60 days for omeprazole (5 mg/mL), pantoprazole (3 mg/mL) and esomeprazole (3 mg/mL) were established. Read more SEE PRODUCT